You have 9 free searches left this month | for more free features.

Atezolizumab plus Bevacizumab

Showing 1 - 25 of 2,648

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus Trial (I-125 Seeds Brachytherapy in PVTT,

Not yet recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • I-125 Seeds Brachytherapy in PVTT
  • +2 more
  • (no location specified)
Aug 14, 2023

Hepatocellular Carcinoma, Atezolizumab-bevacizumab, Response Evaluation Trial in Seoul (Early response evaluation)

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Early response evaluation
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Feb 28, 2023

Hepatocellular Carcinoma Trial in Guangzhou (TACE-HACI, plus atezolizumab-bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • TACE-HACI, plus atezolizumab-bevacizumab
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 20, 2023

Hepatocellular Carcinoma Trial (Ezurpimtrostat, Atezolizumab, Bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Grenoble, France
    University Hospital
Dec 23, 2022

Hepatocellular Carcinoma Trial in Seoul (Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Seoul, Korea, Republic of
    Asan Medical Center
Nov 14, 2023

Hepatocellular Carcinoma Trial (NP137, Atezolizumab, Bevacizumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Sep 23, 2022

Immunotherapy Trial in Heidelberg (Fecal microbiota transfer, Vancomycin Oral Capsule, Atezolizumab + Bevacizumab)

Not yet recruiting
  • Immunotherapy
  • Fecal microbiota transfer
  • +4 more
  • Heidelberg, Baden-Württemberg, Germany
  • +1 more
Jan 19, 2023

Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable Trial in Seoul (Atezolizumab plus

Recruiting
  • Hepatocellular Carcinoma
  • +4 more
  • Atezolizumab plus bevacizumab, combined EBRT to vascular invasion
  • Atezolizumab plus bevacizumab
  • Seoul, Korea, Republic of
    Asan Medical Center
Aug 7, 2023

Patterns of Transcatheter Arterial Chemoembolization Combined

Not yet recruiting
  • HCC
  • (no location specified)
Aug 29, 2023

Hepatocellular Carcinoma Trial (Atezolizumab, Bevacizumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Oct 18, 2023

Hepatocellular Carcinoma Non-resectable Trial in Taoyuan City (Atezolizumab, Bevacizumab, Proton radiotherapy)

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Taoyuan City, Taiwan
    Chang Gung Memorial Hospital at Linkou
Nov 17, 2023

Carcinoma, Hepatocellular Trial (Atezolizumab, Bevacizumab, Tiragolumab)

Not yet recruiting
  • Carcinoma, Hepatocellular
  • (no location specified)
Jun 14, 2023

Colorectal Cancer Trial (all trans Retinoic Acid, Atezolizumab, Bevacizumab)

Not yet recruiting
  • Colorectal Cancer
  • all trans Retinoic Acid
  • +2 more
  • (no location specified)
Aug 11, 2023

Metastatic Hepatocellular Carcinoma Trial in Houston (Atezolizumab, Bevacizumab, ADI-PEG 20)

Not yet recruiting
  • Metastatic Hepatocellular Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 24, 2023

Hepatocellular Carcinoma, Portal Vein Tumour Thrombosis Trial in Canada (Neoadjuvant)

Recruiting
  • Hepatocellular Carcinoma
  • Portal Vein Tumour Thrombosis
  • Neoadjuvant
  • Calgary, Alberta, Canada
  • +6 more
Oct 18, 2022

HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor Trial in France (Ipilimumab Injection, Atezolizumab

Not yet recruiting
  • HCC - Hepatocellular Carcinoma
  • +2 more
  • Ipilimumab Injection
  • +2 more
  • Créteil, France
  • +7 more
Dec 27, 2022

Hepatocellular Carcinoma Trial in Vienna (FMT combined with Atezolizumab plus Bevacizumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • FMT combined with Atezolizumab plus Bevacizumab
  • Vienna, Austria
    Medical University of Vienna
Feb 19, 2023

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC Trial in Worldwide (Atezolizumab, Bevacizumab, Carboplatin)

Active, not recruiting
  • EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
  • Großhansdorf, Germany
  • +17 more
Jan 12, 2023

Recurrent Liver Cancer After Liver Transplantation Trial (Hepatic arterial infusion chemo + Atezolizumab and bevacizumab)

Not yet recruiting
  • Recurrent Liver Cancer After Liver Transplantation
  • Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
  • (no location specified)
Apr 17, 2023

Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma Trial (Atezolizumab Injection, Bevacizumab, Transarterial

Not yet recruiting
  • Hepatocellular Carcinoma
  • BCLC Stage B Hepatocellular Carcinoma
  • Atezolizumab Injection
  • +2 more
  • (no location specified)
Mar 16, 2023

Melanoma Trial in Beijing City, Fuzhou City, Zhejiang (Atezolizumab, Bevacizumab)

Active, not recruiting
  • Melanoma
  • Beijing City, China
  • +2 more
Dec 13, 2022

Hepatocellular Carcinoma Trial in Seoul (AtezoBev with combined radiotherapy)

Not yet recruiting
  • Hepatocellular Carcinoma
  • AtezoBev with combined radiotherapy
  • Seoul, Korea, Republic of
    Severance hospital
Jun 9, 2023

Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8 Trial

Recruiting
  • Resectable Hepatocellular Carcinoma
  • +4 more
  • Atezolizumab
  • +2 more
  • Houston, Texas
  • +1 more
Oct 12, 2022

Hepatocellular Carcinoma, Portal Vein Thrombosis Trial in Seoul (PBT and atezolizumab/bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Portal Vein Thrombosis
  • PBT and atezolizumab/bevacizumab
  • Seoul, Korea, Republic of
    Samsung Medical Center
Nov 15, 2022

Refractory Metastatic Colorectal Cancer, pMMR, MSS Trial in United States (RP2, RP3, atezolizumab)

Not yet recruiting
  • Refractory Metastatic Colorectal Cancer
  • +2 more
  • RP2
  • +3 more
  • Los Angeles, California
  • +5 more
Feb 24, 2023